In vitro, this study showed that unfermented soy milk (USM) and kefir fermented soy milk (FSM) inhibited pancreas lipase with (IC₅₀ = 52.17 and 39.37 μg/mL) and α-amylase activities with (IC₅₀ = 72.60 and 52.71 μg/mL respectively). The most powerful lipase and α -amylase inhibitory activity was observed around 16 h of fermentation.

In HFFD rats, the supplement of FSM increased locomotor performance; and decreased intestinal and pancreas lipase activity by 34 and 35% as compared to untreated HDF-rats. This leads to decrease in TC and LDL-c by 24 and 66%; and increase in HDL-c rates of HFFD-rats by 32%, which helped to decrease in body weight by 20%. Moreover administration of FSM to HFFD-rats inhibited intestinal and pancreas α-amylase activity by 26 and 31% as compared to untreated HFFD-rats, and consequently decrease of blood glucose by 36%. In addition, FSM efficiently was protected from hepatic and kidney tissues toxicities.

在体外，这项研究表明未发酵的豆浆（USM）和开菲尔发酵的豆浆（FSM）抑制胰腺脂肪酶的（IC ₅₀  = 52.17和39.37μg/ mL）和α-淀粉酶活性（IC ₅₀  = 72.60和52.71μg / mL）。发酵约16小时观察到最强大的脂肪酶和α-淀粉酶抑制活性。

在HFFD大鼠中，补充FSM可增加运动能力。与未经处理的HDF大鼠相比，其肠道和胰腺脂肪酶活性降低了34％和35％。这导致TC和LDL-c降低了24％和66％；HFFD大鼠的HDL-c率增加了32％，这有助于减轻体重20％。此外，与未治疗的HFFD-大鼠相比，向HFFD-大鼠施用FSM将肠和胰腺α-淀粉酶活性抑制了26％和31％，因此使血糖降低了36％。此外，FSM被有效地保护免受肝和肾组织毒性。